2014
Genotype and risk of major bleeding during warfarin treatment
Kawai V, Cunningham A, Vear S, Van Driest S, Oginni A, Xu H, Jiang M, Li C, Denny J, Shaffer C, Bowton E, Gage B, Ray W, Roden D, Stein C. Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics 2014, 15: 1973-1983. PMID: 25521356, PMCID: PMC4304738, DOI: 10.2217/pgs.14.153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiological Specimen BanksCytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemCytochrome P450 Family 4Dose-Response Relationship, DrugEthnicityFemaleGene FrequencyGenetic Association StudiesGenetic VariationGenotypeHemorrhageHumansMaleMiddle AgedRisk FactorsVitamin K Epoxide ReductasesWarfarin
2012
Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping
Schildcrout J, Denny J, Bowton E, Gregg W, Pulley J, Basford M, Cowan J, Xu H, Ramirez A, Crawford D, Ritchie M, Peterson J, Masys D, Wilke R, Roden D. Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping. Clinical Pharmacology & Therapeutics 2012, 92: 235-242. PMID: 22739144, PMCID: PMC3785311, DOI: 10.1038/clpt.2012.66.Peer-Reviewed Original ResearchConceptsVanderbilt University Medical CenterAdverse eventsPreemptive genotypingPotential adverse eventsUniversity Medical CenterHome patientsPharmacogenetic associationsMedical CenterVariant allelesMedicationsDrug outcomesPatient safetyDrug decision makingRelevant genetic variantsRoutine integrationTarget drugsGenetic variantsOutcomesFrequency of opportunitiesGenotypingSafetyPrescribingPatientsCohortPharmacogenetics